Skip to main content
. 2023 Sep 19;11(9):e007630. doi: 10.1136/jitc-2023-007630

Figure 1.

Figure 1

CONSORT diagram of patients investigated in the study. In this ADOREG study, we investigated patients who received adjuvant BRAF/MEKi therapy (n=242) or adjuvant anti-PD1 therapy (n=273). Among patients receiving adjuvant BRAF/MEKi therapy 154 did not show any tumor recurrence in the observation period, while among the 71 patients who progressed to stage IV and received subsequent systemic treatments 28 patients achieved disease control without disease progression at the time of data cut-off. By contrast, among all patients who received adjuvant anti-PD1 treatment, 124 patients did not show a tumor recurrence. Among patients who progressed to metastatic stage IV upon adjuvant anti-PD1 treatment (n=108) 43 achieved disease control without disease progression at the time of data cut-off. Patients who progressed to metastatic stage IV and who did not receive CPI or TT either received best-supportive care (BSC) including locoregional treatments such as surgery or TVEC or deceased prior to initiation of systemic treatments. CONSORT, Consolidated Standards of Reporting Trials; CPI, checkpoint inhibitor; TT, targeted therapy; TVEC, Talimogene laherparepvec.